Scarica l'app Stockscreener
39.14
2.22%
0.85
Dopo l'orario di chiusura:
39.00
-0.14
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$38.29
Aprire:
$38.67
Volume 24 ore:
10.28M
Relative Volume:
1.16
Capitalizzazione di mercato:
$172.63B
Reddito:
$50.91B
Utile/perdita netta:
$18.95B
Rapporto P/E:
9.1856
EPS:
4.261
Flusso di cassa netto:
$1.92B
1 W Prestazione:
-0.74%
1M Prestazione:
+2.17%
6M Prestazione:
-2.85%
1 anno Prestazione:
-23.81%
Intervallo 1D:
$38.56
$39.22
Intervallo di 1 settimana:
$37.96
$39.29
Portata 52W:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
39.14 | 172.63B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,373.70 | 1.22T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.20 | 662.49B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
290.79 | 513.86B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.33 | 361.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
161.10 | 304.26B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-11 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2026-08-27 | Downgrade | Deutsche Bank | Hold → Sell |
| 2026-08-12 | Downgrade | Berenberg | Buy → Hold |
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-18 | Iniziato | Bernstein | Outperform |
| 2026-03-10 | Downgrade | TD Cowen | Buy → Hold |
| 2026-03-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Downgrade | Goldman | Buy → Neutral |
| 2026-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Downgrade | Kepler | Buy → Hold |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Novo Nordisk A/S (NVON.NE) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada
Novo Nordisk A/S (NOVO-B.CO) Seasonal returns chart - Yahoo Finance Singapore
Novo Nordisk A/S (NONOF) Seasonal returns chart - Yahoo Finance Australia
Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.
Moderately bullish activity in Novo Nordisk with shares up 1.27% - TipRanks
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases - Yahoo Finance
Sofie Mørck Jarl appointed new CFO at Copenhagen Airports A/S - GlobeNewswire Inc.
Sofie Mørck Jarl bliver ny CFO i Københavns Lufthavne A/S - GlobeNewswire Inc.
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) - Seeking Alpha
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Court rejects Novo bid to block Lilly obesity drug ads - BioPharma Dive
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
US Judge Denies Novo Nordisk Request To Block Eli Lilly Weight Loss Drug Ads - Yahoo Finance
Eli Lilly defeats Novo Nordisk attempt to halt weight-loss drug ads (LLY:NYSE) - Seeking Alpha
U.S. Judge Denies Injunction: Novo-Nordisk A/S (NVO.US) Loses First Round in Bid to Block Eli Lilly and Co's (LLY.US) Weight-Loss Drug Ads - 富途牛牛
Novo Nordisk Loses US Ruling Over Eli Lilly Obesity Drug Ads - Bloomberg.com
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk - Reuters
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? - The Motley Fool
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results? - Zacks Investment Research
FDA proposal weighs on Novo Nordisk stock as downward price move persists - Traders Union
Weekly Recap: Phase 3 CagriSema efficacy and FDA decision due Q4 - TradingView
Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes - PR Newswire
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Novo Nordisk A/S (NVO) Options ChainYahoo Finance - Yahoo! Finance Canada
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances - Zacks Investment Research
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? - Zacks Investment Research
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility - The Motley Fool
Where Will Novo Stock Be in 10 Years? - The Motley Fool
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market - Zacks Investment Research
$Novo-Nordisk A/S (NVO.US)$ A bullish breakout above the 25-day moving average carries a 70% probability of further upside. It is even more favorable if today's closing price is higher than yesterday's and there is no upper shadow. - Moomoo
Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk - Greater Geneva Bern area (GGBa)
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug Competition - Yahoo Finance
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data - TipRanks
Novo's CagriSema helped women lose 25% of weight on average, analysis shows - Reuters
Prothena's Partnership Strategy: Growth Driver or Limitation? - Zacks Investment Research
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis - CNBC
Denmark’s Novo-Fueled Economy Faces Lower Growth, Watchdog Says - Bloomberg.com
Price to earnings forward of Novo Nordisk A/S Class B – LSIN:0QIU - TradingView
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo Nordisk (NVO) repurchased 39.1 million B shares; treasury shares total 1.2% of share capital. - Stock Titan
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Zacks Investment Research
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.70%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):